KELOWNA, BC / ACCESSWIRE / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, announces that dosing ...

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...